Trial Profile
Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Anetumab ravtansine (Primary) ; Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 May 2020 Status changed from completed to discontinued.
- 27 Feb 2020 Status changed from active, no longer recruiting to completed.
- 11 Sep 2019 Status changed from suspended to active, no longer recruiting.